Each dose increase brings a new wave of potential gastrointestinal symptoms as your receptors adjust to higher concentrations
This not only reduces hunger, but also what many patients describe as food noise the persistent mental preoccupation with eating
Another imminent problem is that the GLP-1RAs that are currently used in the clinical setting are biological macromolecular peptide preparations, such as exenatide and liraglutide, with high production costs that limit their clinical application (231)
Under the White House agreement, these drugs will be available to Medicare beneficiaries at reduced costs, with monthly copays expected to be around $50
doi: 10.1186/s12906-018-2099-7
Andrew Huberman: What Motivates Me as a Scientist "What motivates me is the very real possibility of discovering something in my laboratory that can allow patients to see to see much better, for much longer periods of their life, and maybe even reverse blindness." Andrew D